Loading...

Waters Corporation

WATNYSE
HealthcareMedical - Diagnostics & Research
$351.02
$4.69(1.35%)

Waters Corporation WAT Peers

See (WAT) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
WAT$351.02+1.35%20.9B31.88$11.01N/A
DHR-PB$1,261.26-0.78%916.8B146.01$8.64+0.59%
TMO$401.89+0.89%151.7B23.59$17.04+0.40%
DHR$196.04+2.02%140.3B37.92$5.17+0.59%
IDXX$524.91+0.52%42.2B48.47$10.83N/A
A$115.76+1.60%32.9B28.51$4.06+0.85%
IQV$152.29+3.34%26.3B20.80$7.32N/A
MTD$1,183.57+1.63%24.6B29.58$40.01N/A
NTRA$163.76-1.06%22.4B-111.40-$1.47N/A
DGX$174.32+0.39%19.5B22.01$7.92+1.75%
Showing 1 to 10 of 89 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

WAT vs DHR-PB Comparison

WAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, WAT stands at 20.9B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, WAT is priced at $351.02, while DHR-PB trades at $1,261.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

WAT currently has a P/E ratio of 31.88, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, WAT's ROE is +0.39%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, WAT is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for WAT.

Stock Price Comparison

Loading...

Frequently Asked Questions